Fast Track Group FTRK 深 滬
等待開盤 03-26 09:30:00 美东时间
0.4201
-0.090
-17.63%
華盛通- 最 高0.52
- 今 開0.52
- 成交量 8.68万股
- 最 低 0.4197
- 昨 收 0.51
- 總市值 916.34万
- 52周最高 9.69
- 市盈率 靜 --
- 換手率 0.40%
- 52周最低 0.2916
- 委 比 0.00%
- 總股本 2181.25万
- 歷史最高 9.69
- 量 比 4.63
- 振 幅 19.67%
- 歷史最低 0.2916
- 每 手 1
- 風險率 1.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition
Gilead to acquire Ouro Medicines for $1.675 billion, explores Galapagos collaboration, outlines cost-sharing and royalty terms.
03-25 01:58
Radiopharm Drug Shows 90% Accuracy In Detecting Brain Tumors In Trial
Radiopharm Theranostics (ASX: RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today
03-24 19:14
Duality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000
Duality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000 Duality Biotherapeutics published an annual results announcement reporting FY 2025 revenue of RMB 1.9 billion, down 4.61%. FY 2025 loss for the year was RMB 2.6 billion and adjusted loss for the year was
03-23 20:38
Greenwich LifeSciences Expands Breast Cancer Trial Across Major US Cancer Centers, Launches New Study Sites To Advance Cancer Recurrence Therapy
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
03-19 18:05
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
<p>Acrivon Therapeutics reported positive clinical data for ACR-368 in serous endometrial cancer (EC), showing a confirmed overall response rate (cORR) of 52%. The company expanded its Phase 2b study with additional arms targeting broader EC patient populations. ACR-2316, another compound, demonstrated promising activity in lung cancer. The company has strong financials with $118.6 million in cash, supporting operations into 2027.</p>
03-19 11:21
Meta Is Launching A Creator Fast Track Program On Facebook
https://about.fb.com/news/2026/03/creator-fast-track-grow-your-audience-earn-money-on-facebook/
03-19 00:03
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
ProMIS Neurosciences将参加2026年3月17-21日在丹麦哥本哈根举行的AD/PD™ 2026会议，展示两项科学海报，涉及其专有平台在治疗神经退行性疾病中的最新研究。本次会议将突出公司利用EpiSelect™平台开发选择性靶向有毒错误折叠蛋白的治疗方法的成果。此外，公司还将讨论其针对阿尔茨海默病的领先候选药物PMN310的最新进展。
03-18 12:00
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
Zymeworks Inc.'s partner, Jazz Pharmaceuticals, will present four abstracts on zanidatamab at the AACR Annual Meeting, highlighting its potential in treating HER2-expressing cancers. Key findings include significant tumor reduction and manageable safety in early-stage HER2+ breast cancer, insights into its unique HER2 biology, and its efficacy post-T-DXd progression. Additional studies explore its utility across solid tumors and adaptive trial de...
03-18 11:46
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting
Greenwich LifeSciences, Inc. announced updates on its Phase III clinical trial, FLAMINGO-01, evaluating GLSI-100, an immunotherapy for preventing breast cancer recurrences. Two abstracts and posters were accepted for presentation at the AACR Annual Meeting 2026, focusing on immune response data and trial design. GLSI-100 has shown a 70-80% reduction in recurrence rates in early analysis. The trial, led by prominent oncologists and researchers, is...
03-18 10:00
FDA grants Fast Track designation to Polaryx Therapeutics’ PLX-200 for CLN2 disease
FDA grants Fast Track designation to Polaryx Therapeutics’ PLX-200 for CLN2 disease The FDA granted Fast Track designation to Polaryx’s PLX-200 for the treatment of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease). Polaryx said the designation supports advancement of its Phase 2 SOTERIA
03-17 20:33
